The demand graph of the global chronic kidney disease (CKD) drugs market is treading along a lucrative track. The importance of healthy kidneys for the human body cannot be underestimated. The kidneys are not only an important body organ, but also a part of the larger human anatomy responsible for several functions. The functions of the kidney in the human body span into several areas of nephrology. Furthermore, kidney disorders can damage several functionalities in the human body. It is safe to assert that several functions of the human body rely on healthy subsistence of the kidneys. It is a matter of attention that kidney failure cannot be reversed, and only a healthy kidney can help restore the corresponding functionalities. Therefore, the total volume of revenues within the global chronic kidney disease (CKD) drugs market is set to rise.
In this report preview, Transparency Market Research furnishes several important trends and propensities that have aided the expansion of the global chronic kidney disease (CKD) drugs market. Furthermore, constant dialysis also necessitates the use of important drugs that can complement the process. Over the course of the next decade, the global chronic kidney disease (CKD) drugs market is set to attract fresh investments. The focus of the healthcare industry on collaborating with drug development entities has given an impetus to market maturity.
Severity of Symptoms of CKD
Several symptomatic tendencies are related to the occurrence of chronic kidney disorders. Kidneys play an important role in ensuring timely and healthy urination, and this functionality is disrupted in the case of diseases kidneys. Furthermore, kidney disorders can disturb the sleeping and eating routines of the masses, creating new opportunities for growth across the global chronic kidney disease (CKD) drugs market. Several new drugs to treat kidney disorders have been developed in recent times. This trend shall cause an uptick in demand across the chronic kidney disease (CKD) drugs market.
Rising Geriatric Population to Drive Demand
A large geriatric population suffers from kidney disorders that can cripple them of basic functioning. Regular dialysis helps these individuals in experiencing temporary relief from kidney and urinal pain. However, it is important to develop drugs that can support patients who do not resort timely dialysis. The occurrence of chronic kidney disease (CKD) in youngsters can be a source of pain and discomfort. Therefore, the use of chronic kidney disease (CKD) drugs in this population group shall rise in the years to follow. Several medical research institutes have recommended new drug formulae for the treatment of kidney disorders.
Importance of Timely Treatment
Chronic kidney diseases can be a source of several other problems such as puffiness of eyes. Inconsistent sleeping patterns, urinary pain, skin irritation, and swollen ankles. Therefore, it is imperative for medical practitioners to ensure kidney disorders are treated and controlled at the earliest. The humongous importance of chronic kidney disease (CKD) drugs post dialysis has given a thrust to market growth. The next decade would be crucial in deciding the growth direction of the global chronic kidney disease (CKD) drugs market.
Growth of North America Market
On the basis of geography, several new regions have acquired fruition in the chronic kidney disease (CKD) drugs market. The healthcare sector of the US has acquired fresh revenues in recent times, mainly due to the inflow of fresh investments. The focus on treating kidney disorders, especially for the geriatric population, has played a vital role in market growth and maturity.
Some of the notable players who have made a mark in the global chronic kidney disease (CKD) drugs market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., and AbbVie Inc.
Rising Cases due to Changes in Lifestyle Habits will accelerate the Growth Prospects of the Chronic Kidney Disease Drugs Market
The chronic kidney disease drugs market will observe profitable growth across the assessment period of 2016-2024. The lifestyle habits of many individuals have changed substantially over time. Hectic schedules and busy routines have resulted in heightened stress levels, which are giving rise to the consumption of alcohol and other addictive substances. Kidney failures are largely caused due to smoking, hypertension, and other aspects. The rapidly changing habits in regards to addictive substances as well as food consumption and the escalating rise in the cases will accelerate the growth prospects of the chronic kidney disease drugs market.
The global Chronic Kidney Disease (CKD) Drugs market has been segmented as follows:
By Drug class |
|
By End User |
|
By Geography |
|
The global chronic kidney disease (CKD) drugs market was worth USD 11.5 bn and is projected to reach a value of USD 15.8 bn by the end of 2024
Chronic kidney disease (CKD) drugs market is anticipated to grow at a CAGR of 3.6% during the forecast period
North America accounted for a major share of the global chronic kidney disease (CKD) drugs market
Chronic kidney disease (CKD) drugs market is driven by increasing burden of kidney disease, need for effective and unique treatments for patients, rapidly ageing global population, and massive technological advancement in the field
Key players in the global chronic kidney disease (CKD) drugs market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., and AbbVie Inc.
Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights
Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology
Section 3 Executive Summary
3.1 Global Chronic Kidney Disease (CKD) Drugs: Market Snapshot
3.2 Market Share Analysis by Region, 2015
3.3 Global Chronic Kidney Disease (CKD) Drugs Market: Opportunity Map
Section 4 Market Overview
4.1 Market Overview
4.2 Global Chronic Kidney Disease (CKD) Drugs Market: Market Indicators
4.3 Global Chronic Kidney Disease (CKD) Drugs Market: Market Outlook
Section 5 Pipeline Analysis
5.1 Chronic Kidney Disease (CKD) Drugs Market: Recent Approvals
5.2 Chronic Kidney Disease (CKD) Drugs Market: Pipeline Analysis
5.3 Global Chronic Kidney Disease (CKD) Pipeline Drugs Market Size (US$ Mn) Forecast, 2018–2024
Section 6 Market Dynamics
6.1 Drivers and Restraints Snapshot Analysis
6.2 Drivers
6.2.1 High prevalence of chronic kidney disease (CKD) worldwide
6.2.2 Promising pipeline and approval of novel molecules
6.2.3 Shift toward value-based health care model
6.2.4 Rise in incidence of cardiovascular disorders and diabetes
6.2.6 Increase in health care spending & improvement in health care infrastructure
6.2.6 Increase in global geriatric population
6.3 Restraints
6.3.1 Competition from biosimilars due to patent loss
6.3.2 Increase in preference for generic drug variants
6.3.3 Change in reimbursement scenario
6.4 Opportunities
6.4.1 Focusing on emerging markets
6.4.2 Novel therapeutic approaches such as stem cell therapy
6.5 Key Trends
6.6 Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, 2014–2024
6.7 Global Chronic Kidney Disease Drugs Market: Porter’s Analysis
Section 7 Chronic Kidney Disease (CKD) Drugs Market Analysis, by Drug Class
7.1 Introduction
7.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class
7.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by Drug Class
7.3.1 ACE Inhibitors
7.3.2 Angiotensin-II Receptor Blockers
7.3.3 Calcium Channel Blockers
7.3.4 Beta Blockers
7.3.5 Erythropoiesis-stimulating Agents (ESAs)
7.3.6 Diuretics
7.3.7 Others
7.5 Market Attractiveness Analysis, by Drug Class
Section 8 Chronic Kidney Disease (CKD) Drugs Market Analysis, by End-user
8.1 Introduction
8.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user
8.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by End-user
8.3.1 Hospitals
8.3.2 Specialty Clinics
8.4 Market Attractiveness Analysis, by End-user
Section 9 Chronic Kidney Disease (CKD) Drugs Market Analysis, by Region
9.1 Global Chronic Kidney Disease (CKD) Drugs Market Snapshot, by Country
9.2 Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region
9.3 Chronic Kidney Disease (CKD) Drugs Market Forecast, by Region
9.4 Market Attractiveness Analysis, by Region
Section 10 North America Chronic Kidney Disease (CKD) Drugs Market Analysis
10.1 Market Overview
10.2 Market Analysis, by Drug Class
10.2.1 Market Value Share Analysis, by Drug Class
10.2.2 Market Size (US$ Mn) Forecast, by Drug Class
10.2.2.1 ACE Inhibitors
10.2.2.2 Angiotensin-II Receptor Blockers
10.2.2.3 Calcium Channel Blockers
10.2.2.4 Beta Blockers
10.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
10.2.2.6 Diuretics
10.2.2.7 Others
10.3 Market Analysis, by End-user
10.3.1 Market Value Share Analysis, by End-user
10.3.2 Market Size (US$ Mn) Forecast, by End-user
10.3.2.1 Hospitals
10.3.2.2 Specialty Clinics
10.4 Market Analysis, by Country
10.4.1 Market Value Share Analysis, by Country
10.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
10.4.2.1 U.S.
10.4.2.2 Canada
10.5 Market Attractiveness Analysis
10.5.1 by Drug Class
10.5.2 by End-user
10.5.3 by Country
Section 11 Europe Chronic Kidney Disease (CKD) Drugs Market Analysis
11.1 Market Overview
11.2 Market Analysis, by Drug Class
11.2.1 Market Value Share Analysis, by Drug Class
11.2.2 Market Size (US$ Mn) Forecast, by Drug Class
11.2.2.1 ACE Inhibitors
11.2.2.2 Angiotensin-II Receptor Blockers
11.2.2.3 Calcium Channel Blockers
11.2.2.4 Beta Blockers
11.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
11.2.2.6 Diuretics
11.2.2.7 Others
11.3 Market Analysis, by End-user
11.3.1 Market Value Share Analysis, by End-user
11.3.2 Market Size (US$ Mn) Forecast, by End-user
11.3.2.1 Hospitals
11.3.2.2 Specialty Clinics
11.4 Market Analysis, by Country
11.4.1 Market Value Share Analysis, by Country
11.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
11.4.2.1 U.K.
11.4.2.2 Germany
11.4.2.3 France
11.4.2.4 Spain
11.4.2.5 Italy
11.4.2.6 Rest of Europe
11.5 Market Attractiveness Analysis
11.5.1 by Drug Class
11.5.2 by End-user
11.5.3 by Country
Section 12 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis
12.1 Market Overview
12.2 Market Analysis, by Drug Class
12.2.1 Market Value Share Analysis, by Drug Class
12.2.2 Market Size (US$ Mn) Forecast, by Drug Class
12.2.2.1 ACE Inhibitors
12.2.2.2 Angiotensin-II Receptor Blockers
12.2.2.3 Calcium Channel Blockers
12.2.2.4 Beta Blockers
12.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
12.2.2.6 Diuretics
12.2.2.7 Others
12.3 Market Analysis, by End-user
12.3.1 Market Value Share Analysis, by End-user
12.3.2 Market Size (US$ Mn) Forecast, by End-user
12.3.2.1 Hospitals
12.3.2.2 Specialty Clinics
12.4 Market Analysis, by Country
12.4.1 Market Value Share Analysis, by Country
12.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
12.4.2.1 China
12.4.2.2 Japan
12.4.2.3 Australia
12.4.2.4 India
12.4.2.5 Rest of Asia Pacific
12.5 Market Attractiveness Analysis
12.5.1 by Drug Class
12.5.2 by End-user
12.5.3 by Country
Section 13 Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis
13.1 Market Overview
13.2 Market Analysis, by Drug Class
13.2.1 Market Value Share Analysis, by Drug Class
13.2.2 Market Size (US$ Mn) Forecast, by Drug Class
13.2.2.1 ACE Inhibitors
13.2.2.2 Angiotensin-II Receptor Blockers
13.2.2.3 Calcium Channel Blockers
13.2.2.4 Beta Blockers
13.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
13.2.2.6 Diuretics
13.2.2.7 Others
13.3 Market Analysis, by End-user
13.3.1 Market Value Share Analysis, by End-user
13.3.2 Market Size (US$ Mn) Forecast, by End-user
13.3.2.1 Hospitals
13.3.2.2 Specialty Clinics
13.4 Market Analysis, by Country
13.4.1 Market Value Share Analysis, by Country
13.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
13.4.2.1 Brazil
13.4.2.2 Mexico
13.4.2.3 Rest of LATAM
13.5 Market Attractiveness Analysis
13.5.1 by Drug Class
13.5.2 by End-user
13.5.3 by Country
Section 14 Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis
14.1 Market Overview
14.2 Market Analysis, by Drug Class
14.2.1 Market Value Share Analysis, by Drug Class
14.2.2 Market Size (US$ Mn) Forecast, by Drug Class
14.2.2.1 ACE Inhibitors
14.2.2.2 Angiotensin-II Receptor Blockers
14.2.2.3 Calcium Channel Blockers
14.2.2.4 Beta Blockers
14.2.2.5 Erythropoiesis-stimulating Agents (ESAs)
14.2.2.6 Diuretics
14.2.2.7 Others
14.3 Market Analysis, by End-user
14.3.1 Market Value Share Analysis, by End-user
14.3.2 Market Size (US$ Mn) Forecast, by End-user
14.3.2.1 Hospitals
14.3.2.2 Specialty Clinics
14.4 Market Analysis, by Country
14.4.1 Market Value Share Analysis, by Country
14.4.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
14.4.2.1 South Africa
14.4.2.2 Saudi Arabia
14.4.2.3 Rest of MEA
14.5 Market Attractiveness Analysis
14.5.1 by Drug Class
14.5.2 by End-user
14.5.3 by Country
Section 15 Company Profiles
15.1 Chronic Kidney Disease (CKD) Drugs Market Share Analysis, by Company (2015)
15.2 Company Profiles
15.2.1 Keryx Biopharmaceuticals, Inc.
15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2 Financial Overview
15.2.1.3 Product Portfolio
15.2.1.4 SWOT Analysis
15.2.1.5 Strategic Overview
15.2.2 Kissei Pharmaceutical Co., Ltd
15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2 Financial Overview
15.2.2.3 Product Portfolio
15.2.2.4 SWOT Analysis
15.2.2.5 Strategic Overview
15.2.3 AbbVie, Inc.
15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2 Financial Overview
15.2.3.3 Product Portfolio
15.2.3.4 SWOT Analysis
15.2.3.5 Strategic Overview
15.2.4 GlaxoSmithKline plc.
15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2 Financial Overview
15.2.4.3 Product Portfolio
15.2.4.4 SWOT Analysis
15.2.4.5 Strategic Overview
15.2.5 Sanofi S.A.
15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2 Financial Overview
15.2.5.3 Product Portfolio
15.2.5.4 SWOT Analysis
15.2.5.5 Strategic Overview
15.2.6 F. Hoffmann-La Roche Ltd.
15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2 Financial Overview
15.2.6.3 Product Portfolio
15.2.6.4 SWOT Analysis
15.2.6.5 Strategic Overview
15.2.7 Pfizer, Inc.
15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2 Financial Overview
15.2.7.3 Product Portfolio
15.2.7.4 SWOT Analysis
15.2.7.5 Strategic Overview
15.2.8 AstraZeneca plc
15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2 Financial Overview
15.2.8.3 Product Portfolio
15.2.8.4 SWOT Analysis
15.2.8.5 Strategic Overview
15.2.9 Amgen Inc.
15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2 Financial Overview
15.2.9.3 Product Portfolio
15.2.9.4 SWOT Analysis
15.2.9.5 Strategic Overview
15.2.10 Teva Pharmaceutical Industries Ltd.
15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2 Financial Overview
15.2.10.3 Product Portfolio
15.2.10.4 SWOT Analysis
15.2.10.5 Strategic Overview
List of Tables
Table 01: Global Chronic Kidney Disease (CKD) Pipeline Drugs Market Size (US$ Mn) Forecast, 2018–2024
Table 02: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 03: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 04: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 05: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 06: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 07: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 08: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 09: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 10: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 12: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 13: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 14: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 15: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 16: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 18: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 19: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
List of Figures
Figure 01: Global Parsabiv (Etelcalcitide) Market Revenue, 2018 – 2024 (US$ Mn)
Figure 02: Global Forxiga (Dapagliflozin Market Revenue, 2021 – 2024 (US$ Mn)
Figure 03: Global Roxadustat (FG-4592) Market Revenue, 2018 – 2024 (US$ Mn)
Figure 04: Global Daprodustat Market Revenue, 2020 – 2024 (US$ Mn)
Figure 05: Global Vadadustat Market Revenue, 2020 – 2024 (US$ Mn)
Figure 06: Global Alpharen Market Revenue, 2020 – 2024 (US$ Mn)
Figure 07: Global Chronic Kidney Disease Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 08: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 09: Global ACE Inhibitors Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Angiotensin-II Receptor Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Global Calcium Channel Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Beta Blockers Market Revenue (US$ Mn) and Y-o-Y Growth (%) 2014–2024
Figure 13: Global Erythropoiesis-stimulating agents (ESAs) Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 14: Global Diuretics Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 15: Global Other Drug Class Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 16: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class
Figure 17: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2016 and 2024
Figure 18: Global Hospitals Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 19: Global Specialty Clinics Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 20: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user
Figure 21: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 22: Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Region
Figure 23: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2024
Figure 24: North America Market Attractiveness Analysis, by Country
Figure 25: North America Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 26: North America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 27: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 28: North America Market Attractiveness Analysis, by Drug Class
Figure 29: North America Market Attractiveness Analysis, by End-user
Figure 30: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2024
Figure 31: Europe Market Attractiveness Analysis, by Country
Figure 32: Europe Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 33: Europe Market Value Share Analysis, by End-user, 2016 and 2024
Figure 34: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: Europe Market Attractiveness Analysis, by Drug Class
Figure 36: Europe Market Attractiveness Analysis, by End-user
Figure 37: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 38: Asia Pacific Market Attractiveness Analysis, by Country
Figure 39: Asia Pacific Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 40: Asia Pacific Market Value Share Analysis, by End-user, 2016 and 2024
Figure 41: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class
Figure 43: Asia Pacific Market Attractiveness Analysis, by End-user
Figure 44: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 45: Latin America Market Attractiveness Analysis, by Country
Figure 46: Latin America Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 47: Latin America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 48: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 49: Latin America Market Attractiveness Analysis, by Drug Class
Figure 50: Latin America Market Attractiveness Analysis, by End-user
Figure 51: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2014–2024
Figure 52: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 53: Middle East & Africa Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 54: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2024
Figure 55: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class
Figure 57: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 58: Global Chronic Kidney Disease (CKD) Drugs Market Share Analysis, by Company (2015)